RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is pleased to announce that the first human implantation of the company’s map3® Cellular Allogeneic Bone Graft Strips Allograft took place during an anterior lumbar interbody fusion (ALIF) procedure last week. The map3 Strips Allograft implant will expand the company's current cellular allogeneic bone graft portfolio when it launches later in 2014.
Map3 Strips Allograft is an implant that contains the three essential elements necessary for bone formation in a single allograft: a three-dimensional osteoconductive scaffold, demineralized bone matrix (DBM) that demonstrates verified osteoinductive potential and multipotent adult progenitor (MAPC®) class cells that provide osteogeneic and angiogeneic signals to support the bone healing process. This moldable implant is designed for ease of use, and its flexible yet cohesive properties make it ideal for filling bone voids in applications such as small joint repair, irregular defects or as an onlay in the posterolateral spine.
“Map3 Cellular Allogeneic Bone Graft is a promising biologic implant, and the strips configuration offers another option,” said Vittorio M. Morreale, MD, a neurosurgeon at Henry Ford Hospital in Detroit. “Not only does map3 have a three-dimensional osteoconductive scaffold but it also has DBM that demonstrates verified osteoinductive potential and viable MAPC-class cells that provide osteogeneic and angiogeneic signals. Both configurations provide excellent handling and surgical placement of the implant, and the addition of strips gives me options depending on what the case needs.”
“Initial feedback from surgeons about the strips configuration has been very positive, and we are excited to work with Dr. Morreale on the first implantation,” said Brian K. Hutchison, RTI president and CEO. “We anticipate a market release of the strips implant later this year, which will complement our current map3 Chips Allograft offering.”
The map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 incorporates MAPC-based technology with stem cells isolated from the same donor as the bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. To learn more about map3, visit www.map3.com, a website designed to educate surgeons and patients about map3 and MAPC-based technology.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit http://www.rtix.com/.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.
Contacts:
Jenny Highlander, APR, 386-418-8888
Director,
Corporate Communications
